Emerging genetic and pharmacologic therapies for controlling hemostasis: Beyond recombinant clotting factors

Hematology (United States)

Volumn 2015, Issue 1, 2015, Pages 33-40

  Monahan, Paul E ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Department of Pediatrics ^*  (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; IMMUNOGLOBULIN G ANTIBODY; LENTIVIRUS VECTOR; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; TISSUE FACTOR PATHWAY INHIBITOR; ANTITHROMBIN; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR; EMICIZUMAB; F8 PROTEIN, HUMAN; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

BLOOD CLOTTING; CELL THERAPY; CLINICAL TRIAL (TOPIC); DISSEMINATED INTRAVASCULAR CLOTTING; EX VIVO GENE TRANSFER; GENE THERAPY; GENE TRANSFER; HEALTH CARE QUALITY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; NONHUMAN; PHARMACEUTICAL CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; GENE VECTOR; GENETICS; LENTIVIRINAE; PHENOTYPE; PROCEDURES; RNA INTERFERENCE; TREATMENT OUTCOME;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTITHROMBINS; BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; FACTOR IX; FACTOR VIII; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMANS; LENTIVIRUS; LIPOPROTEINS; PHENOTYPE; RNA INTERFERENCE; TREATMENT OUTCOME;

EID: 85010953465     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2015.1.33     Document Type: Review

References (62)

1. Shetty S, Ghosh K. Novel therapeutic approaches for haemophilia. Haemophilia. 2015;21(2):152-161.
2. Chuah MK, Evens H, VandenDriessche T. Gene therapy for hemophilia. J Thromb Haemost. 2013;11(Suppl 1):99-110.
3. Monahan PE. Gene therapy in an era of emerging treatment options for hemophilia B. J Thromb Haemost. 2015;13(Suppl 1):S151-160.
4. Hastie E, Samulski RJ. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success-a personal perspective. Hum Gene Ther. 2015;26(5):257-265.
5. Li C, Narkbunnam N, Samulski RJ, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 2012;19(3):288-294.
6. Crudele JM, Finn JD, Siner JI, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood. 2015;125(10):1553-1561.
7. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-347.
8. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8(16):1248-1254.
9. Wu Z, Sun J, Zhang T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther. 2008;16(2):280-289.
10. Nathwani AC, Gray JT, McIntosh J, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood. 2007;109(4):1414-1421.
11. Ward NJ, Buckley SM, Waddington SN, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood. 2011;117(3):798-807.
12. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
13. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994-2004.
14. den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011; 17(1):41-44.
15. Monahan PE, Sun J, Gui T, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther. 2015;26:1-13.
16. Cantore A, Ranzani M, Bartholomae CC, et al. Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Sci Transl Med. 2015;7(277):277ra228.
17. Monahan PE, Walsh CE, Powell JS, et al. [LB010] Update on a phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B. J Thromb Haemost. 2015;13(Suppl 2):87.
18. Herzog RW. Hemophilia gene therapy: caught between a cure and an immune response. Mol Ther. 2015;23(9):1411-1412.
19. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704-712.
20. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199(3):381-390.
21. Calcedo R, Morizono H, Wang L, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol. 2011;18(9):1586-1588.
22. Tse LV, Moller-Tank S, Asokan A. Strategies to circumvent humoral immunity to adeno-associated viral vectors. Expert Opin Biol Ther. 2015;15(6):845-855.
23. Miesbach WA, Meyer C, Nijmeijer B, et al. Phase 1-2 clinical trial of a recombinant AAV5 vector containing the human FIX gene in patients with severe or moderately severe Haemophilia B. Blood. 2014;124(21): 5948-5948.
24. Nair N, Rincon MY, Evens H, et al. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. Blood. 2014;123(20):3195-3199.
25. Anguela XM, Sharma R, Doyon Y, et al. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood. 2013;122(19):3283-3287.
26. Holmes MC. Genome editing with zinc finger nucleases for hemophilia A and B. Paper presented at London Hemophilia Conference. January 2015. London, U.K.
27. Annoni A, Cantore A, Della Valle P, et al. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. EMBO Mol Med. 2013;5(11):1684-1697.
28. Monahan PE, Lothrop CD, Sun J, et al. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther. 2010;18(11):1907-1916.
29. McIntosh J, Lenting PJ, Rosales C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 2013;121(17):3335-3344.
30. Suwanmanee T, Hu G, Gui T, et al. Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice. Mol Ther. 2014;22(3):567-574.
31. Fomin ME, Togarrati PP, Muench MO. Progress and challenges in the development of a cell-based therapy for hemophilia A. J Thromb Haemost. 2014;12(12):1954-1965.
32. Doering CB, Spencer HT. Replacing bad (F)actors: hemophilia. Hematology Am Soc Hematol Educ Program. 2014;2014(1):461-467.
33. Park CY, Kim J, Kweon J, et al. Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Proc Natl Acad Sci U S A. 2014;111(25):9253-9258.
34. Menon T, Firth AL, Scripture-Adams DD, et al. Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs. Cell Stem Cell. 2015;16(4):367-372.
35. Du LM, Nurden P, Nurden AT, et al. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun. 2013;4:2773.
36. Shi Q, Schroeder JA, Kuether EL, Montgomery RR. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies. J Thromb Haemost. 2015;13(7):1301-1309.
37. Chen Y, Schroeder JA, Kuether EL, Zhang G, Shi Q. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice. Mol Ther. 2014;22(1):169-177.
38. Greene TK, Lyde RB, Bailey SC, et al. Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy. J Thromb Haemost. 2014;12(12): 2102-2112.
39. Wang X, Shin SC, Chiang AF, et al. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A. Mol Ther. 2015;23(4):617-626.
40. Shima M. The potential of bispecific antibodies for treatment of hemophilia A. XXV Congress of the International Society on Thrombosis and Haemostasis. June 20-25, 2015. Toronto, Canada. Vol. 13; 2015:AS015.
41. Erhardtsen E, Ezban M, Madsen MT, et al. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis. 1995;6(5): 388-394.
42. Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743-754.
43. Scheiflinger F, Dockal M, Rosing J, Kerschbaumer RJ. Enhancement of the enzymatic activity of activated coagulation factor IX by anti-factor IX antibodies. J Thromb Haemost. 2008;6(2):315-322.
44. Dockal M, Hartmann R, Fries M, et al. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). J Biol Chem. 2014;289(3):1732-1741.
45. Peyvandi F, Garagiola I. Treatment of hemophilia in the near future. Semin Thromb Hemost. Prepublished on Feb 19, 2015, as DOI 10.1055/s-0034-1543998.
46. Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21(5):492-497.
47. Sehgal A. Antithrombin reduction improves coagulation in rare bleeding disorder plasma. XXV Congress of the International Society on Thrombosis and Haemostasis. June 20-25, 2015. Vol. 13; 2015:AS015.
48. Centers for Disease Control and Prevention. Report on the universal data collection program, 2005-2009 (http://www.cdc.gov/ncbddd/blooddisorders/udc/documents/report-udcprogram-january2005-december-2009-jan-2014.pdf). Accessed January 26, 2014.
49. Puetz J, Soucie JM, Kempton CL, Monahan PE. Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database. Haemophilia. 2013;20(1):25-31.
50. Baker JR, Riske B, Drake JH, et al. US Hemophilia Treatment Center population trends 1990-2010: patient diagnoses, demographics, health services utilization. Haemophilia. 2013;19(1):21-26.
51. Soucie JM, Richardson LC, Evatt BL, et al. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males. Transfusion. 2001;41(3):338-343.
52. Buchlis G, Podsakoff CM, Radu A, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood. 2012;119:3038-3041.
53. Nathwani AC, Gray JT, McIntosh J et al. Safe and efficient trasnduction of the liver after peripheral vein infusion of self-complementary AAV results in stable therapeutic expression of FIX in nonhuman primates. Blood. 2007;109:1414-1421.
54. Sabatino DE, Lange AM, Altynova ES, et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther. 2011;19:442-449
55. Arruda VR, Stedman HH, Nichols TC, et al. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood. 2005;105:3458-3464.
56. Niemeyer GP, Herzog RW, Mount J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood. 2009;113:797-806.
57. Nichols TC, Whitford MH, Arruda VR, et al. Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. Hum Gene Ther Clin Dev. 2015;26:5-14.
58. Liu Q, Huang W, Zhang H, et al. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther. 2014;21: 732-738.
59. Veron P, Leborgne C, Monteilhet V, et al. Humoral and cellular capsid-specific immune responses to adenoassociated virus type 1 in randomized healthy donors. J Immunol. 2012;188:6418-6424.
60. Hurlbut GD, Ziegler RJ, Nietupski JB, et al. Preexisting immunity and low expression in primates highlight translational challenges for liverdirected AAV8-mediated gene therapy. Mol Ther. 2010;18:1983-1994.
61. Halbert CL, Miller AD, McNamara S, et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther. 2006;17:440-447.
62. Erles K, Sebökovà P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adenoassociated virus (AAV). J Med Virol. 1999;59:406-411.